EyePoint Pharmaceuticals, Inc. (EYPT)
NASDAQ: EYPT · Real-Time Price · USD
8.38
-0.58 (-6.42%)
Nov 21, 2024, 2:54 PM EST - Market open
EyePoint Pharmaceuticals Employees
EyePoint Pharmaceuticals had 121 employees as of December 31, 2023. The number of employees decreased by 23 or -15.97% compared to the previous year.
Employees
121
Change (1Y)
-23
Growth (1Y)
-15.97%
Revenue / Employee
$377,793
Profits / Employee
-$855,950
Market Cap
587.94M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
InnovAge Holding | 2,350 |
agilon health | 1,117 |
Definitive Healthcare | 950 |
Exscientia | 483 |
Phathom Pharmaceuticals | 452 |
Butterfly Network | 225 |
Entrada Therapeutics | 159 |
IRADIMED CORPORATION | 148 |
EYPT News
- 7 days ago - EyePoint Pharmaceuticals: Low Price And Good Data Create An Opportunity - Seeking Alpha
- 17 days ago - EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences - GlobeNewsWire
- 20 days ago - EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares - GlobeNewsWire
- 22 days ago - EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering - GlobeNewsWire
- 23 days ago - EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock - GlobeNewsWire
- 24 days ago - EyePoint Pharmaceuticals Announces Positive Interim 16-Week Data for Ongoing Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema - GlobeNewsWire
- 4 weeks ago - EyePoint Pharmaceuticals Announces First Patient Dosed in Global Phase 3 LUGANO Clinical Trial of DURAVYUTM for the Treatment of Wet Age-Related Macular Degeneration - GlobeNewsWire
- 5 weeks ago - EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire